First-line therapy of chronic myeloid leukemia – focus on dasatinib

Philip C AmreinHematology-Oncology, Massachusetts General Hospital, Boston, USAAbstract: Dasatinib is a broad spectrum, ATP-competitive, tyrosine kinase inhibitor with low nM activity against Bcr-Abl, Src, and other tyrosine kinases. This activity has allowed dasatinib to emerge as one of the most e...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Amrein PC
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://doaj.org/article/8e4489f7dd2b4887984e6baf19837865
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:8e4489f7dd2b4887984e6baf19837865
record_format dspace
spelling oai:doaj.org-article:8e4489f7dd2b4887984e6baf198378652021-12-02T04:15:07ZFirst-line therapy of chronic myeloid leukemia – focus on dasatinib1179-9889https://doaj.org/article/8e4489f7dd2b4887984e6baf198378652012-04-01T00:00:00Zhttp://www.dovepress.com/first-line-therapy-of-chronic-myeloid-leukemia-ndash-focus-on-dasatini-a9750https://doaj.org/toc/1179-9889Philip C AmreinHematology-Oncology, Massachusetts General Hospital, Boston, USAAbstract: Dasatinib is a broad spectrum, ATP-competitive, tyrosine kinase inhibitor with low nM activity against Bcr-Abl, Src, and other tyrosine kinases. This activity has allowed dasatinib to emerge as one of the most effective agents in the treatment of chronic myeloid leukemia (CML), and dasatinib has become the third drug over the past 10 years to be FDA approved for first line therapy in this setting. This review consists of papers and reports that recount the recent dramatic progress that has been made in the understanding of CML on a molecular basis leading up to the new targeted therapies, especially the use of dasatinib. As with any drug, treatment with dasatinib has risks and side effects, especially pleural effusions and anti-platelet effects, as outlined in recently published studies. Of interest are the reports of alternative doses and schedules that may be able to circumvent some of these side effects without compromising the effectiveness of this drug. This review outlines the mode of action, pharmacology, effectiveness, and safety of dasatinib in the treatment of CML, and by comparing dasatinib directly with the other tyrosine kinase inhibitors effective in CML, it describes the place in therapy that dasatinib currently holds.Keywords: dasatinib, CML, chronic myeloid leukemia Amrein PCDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 77-85 (2012)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the blood and blood-forming organs
RC633-647.5
spellingShingle Diseases of the blood and blood-forming organs
RC633-647.5
Amrein PC
First-line therapy of chronic myeloid leukemia – focus on dasatinib
description Philip C AmreinHematology-Oncology, Massachusetts General Hospital, Boston, USAAbstract: Dasatinib is a broad spectrum, ATP-competitive, tyrosine kinase inhibitor with low nM activity against Bcr-Abl, Src, and other tyrosine kinases. This activity has allowed dasatinib to emerge as one of the most effective agents in the treatment of chronic myeloid leukemia (CML), and dasatinib has become the third drug over the past 10 years to be FDA approved for first line therapy in this setting. This review consists of papers and reports that recount the recent dramatic progress that has been made in the understanding of CML on a molecular basis leading up to the new targeted therapies, especially the use of dasatinib. As with any drug, treatment with dasatinib has risks and side effects, especially pleural effusions and anti-platelet effects, as outlined in recently published studies. Of interest are the reports of alternative doses and schedules that may be able to circumvent some of these side effects without compromising the effectiveness of this drug. This review outlines the mode of action, pharmacology, effectiveness, and safety of dasatinib in the treatment of CML, and by comparing dasatinib directly with the other tyrosine kinase inhibitors effective in CML, it describes the place in therapy that dasatinib currently holds.Keywords: dasatinib, CML, chronic myeloid leukemia 
format article
author Amrein PC
author_facet Amrein PC
author_sort Amrein PC
title First-line therapy of chronic myeloid leukemia – focus on dasatinib
title_short First-line therapy of chronic myeloid leukemia – focus on dasatinib
title_full First-line therapy of chronic myeloid leukemia – focus on dasatinib
title_fullStr First-line therapy of chronic myeloid leukemia – focus on dasatinib
title_full_unstemmed First-line therapy of chronic myeloid leukemia – focus on dasatinib
title_sort first-line therapy of chronic myeloid leukemia – focus on dasatinib
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/8e4489f7dd2b4887984e6baf19837865
work_keys_str_mv AT amreinpc firstlinetherapyofchronicmyeloidleukemiaampndashfocusondasatinib
_version_ 1718401384455340032